Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 6/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3722431 | 0.85 | AOC3 (0.47) | MKNK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3706177 | 0.85 | AOC3 (0.47) | MKNK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3718740 | 0.85 | AOC3 (0.47) | MKNK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3720282 | 0.76 | TSHR (0.42) | LMNAL3MBTL1 | |
| SCHEMBL6319993 | 0.75 | SMN1; SMN2 (0.50) | CYP51A1SMN1; SMN2LMNAL3MBTL1ADRB3 | |
| SCHEMBL3719112 | 0.73 | HTT (0.31) | — | |
| SCHEMBL3708246 | 0.72 | PDE10A (0.31) | — | |
| SCHEMBL6643536 | 0.72 | SMN1; SMN2 (0.51) | CYP51A1MKNK1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL6318477 | 0.72 | SMN1; SMN2 (0.51) | CYP51A1MKNK1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL3703555 | 0.72 | HRH1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | BACE1, APP, BACE2 | CYP51A1 244/4885MKNK1 1215/4885SMN1; SMN2 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.